Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind study to determine the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VL-2397 administered by infusion in healthy volunteers for treatment of fungal infections

Next Previous
Search
Trial Profile

A randomized, double-blind study to determine the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VL-2397 administered by infusion in healthy volunteers for treatment of fungal infections

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VL 2397 (Primary)
  • Indications Invasive bronchopulmonary aspergillosis
  • Focus Adverse reactions; First in man; Pharmacokinetics

    • Most Recent Events

    • 19 Aug 2019 Results assessing safety and tolerability and pharmacokinetics of a novel antifungal drug VL-2397 in healthy adults published in the Antimicrobial Agents and Chemotherapy
    • 08 Oct 2017 Results presented at the IDWeek 2017
    • 05 Jun 2017 Results published in a Vical media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top